• Opportunity

    The results of studies to date have prompted globally respected academics, clinicians, institutional investors, and pharmaceutical and nutraceutical corporations to invest significant resources into further development. The potential applications for gut microbiome therapy are profound once the obligate criteria of standardization can be met.

     

    Thus far, collection and processing of stool has been messy, malodorous, labor intensive, and haphazard. Scientific inquiry and clinical studies demand stringent protocols to eliminate variables and improve safety. Recognizing this, regulatory bodies are poised to provide new guidances to better regulate the collection of fecal matter.

     

    The unprepared will fall behind, forced to put research and clinical trials on hold.

    3,000,000

    Microbial genes in our gut microbiota

    150 X

    The number of functional genes in gut microorganisms is ~150 times higher than the number of genes in the human genome

    $658,000,000 USD

    The expected value of the global human microbiome market by 2023

    $121,000,000

    Federal investments in Fiscal Year (FY) 2016 and 2017 funding for cross-ecosystem microbiome studies through White House Office of Science and Technology Policy (OSTP) led National Microbiome Initiative (NMI)

    400%

    Global increase in deaths related to C. difficile from 2000 - 2007

    91%

    Cure rate for single FMT treatment. For those requiring a second FMT procedure, the success rate is 98%.